Pharmaceutical compound
Identifiers | |
---|---|
IUPAC name
| |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C27H32N2O4 |
Molar mass | 448.563 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
PD-0298029 is a drug which acts as a selective antagonist for the muscarinic acetylcholine receptor M4. It was developed for the treatment of Parkinson's disease, but poor bioavailability and rapid metabolism in animal studies have meant its use is largely limited to in vitro research into the M4 and other muscarinic receptors.
See also
References
- Böhme TM, Augelli-Szafran CE, Hallak H, Pugsley T, Serpa K, Schwarz RD (July 2002). "Synthesis and pharmacology of benzoxazines as highly selective antagonists at M(4) muscarinic receptors". Journal of Medicinal Chemistry. 45 (14): 3094–3102. doi:10.1021/jm011116o. PMID 12086495.
- Boehme TM, Angelli-Szafran CE, Corinne E, Hallak H, Schwarz RD (January 2002). "Analogs of M4 selective synthetic muscarinic receptor antagonists: Synthesis, binding and pharmacokinetic properties". Medicinal Chemistry Research. 11 (8): 423–433.
- Eglen RM (2005). "Muscarinic receptor subtype pharmacology and physiology". Progress in Medicinal Chemistry. 43. Amsterdam London: Elsevier Science: 105–136 (128). doi:10.1016/S0079-6468(05)43004-0. ISBN 978-0-444-51572-8. PMID 15850824.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |